View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 12, 2020

Arcturus initiates human trials of potential Covid-19 vaccine

US-based Arcturus Therapeutics has dosed the first group of participants in the Phase I/II clinical study of its Covid-19 vaccine candidate.

US-based Arcturus Therapeutics has dosed the first group of participants in the Phase I/II clinical study of its Covid-19 vaccine candidate.

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

The company said that results from the trial are expected in the fourth quarter of this year.

ARCT-021 is an experimental vaccine, which is being studied with global contract research organisation CTI Clinical Trial and Consulting Services in collaboration with Singapore-based Duke-NUS Medical School. It uses messenger RNA to inoculate against the coronavirus.

In March this year, Arcturus and Duke-NUS collaborated to create a Covid-19 vaccine based on the company’s STARR technology and a Duke-NUS platform designed for the quick screening of vaccines for safety and effectiveness.

The ARCT-021 Phase I/II study comprises two parts. In the Phase I trial, escalating doses will be administered as a single injection to participants aged between 21 and 55.

Based on the results of the safety, immunogenicity, and T-cell response data from this group, dosing regimens will be selected for further evaluation in the Phase II study. This study includes cohorts in younger adults, as well as older adults aged 56-80.

Arcturus president and CEO Joseph Payne said: “We are very pleased to have initiated dosing in our ARCT-021 Phase I/II study, and in fact we have already completed dosing of all subjects in the first cohort of the study.

“Based on preclinical immunogenicity data, our self-replicating mRNA-based investigational vaccine could have a highly differentiated safety and efficacy profile, and may potentially allow vaccination at very low doses, and with a single administration.

“These favourable attributes could greatly facilitate mass vaccination campaigns necessary to control this global pandemic.”

Last month, Arcturus and Duke-NUS Medical School in Singapore received approval from the country’s Health Sciences Authority (HSA) to assess Covid-19 vaccine candidate LUNAR-COV19 in a Phase I/II clinical trial.

Related Companies

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena